A Study On Phased Technology Trading Mechanism Of China's Biomedical Industry

The application and transformation of scientific research achievements has been a long-standing goal of China's economic development for decades.The management has made loud calls,policy encouragement and project funding.Since the beginning of this century,in the face of the turning point of industrial upgrading in China's economic development,the significance of the application of scientific research results has become more and more important.It has determined the output effect of China's science and technology input to the downstream,and has become the driving force for in-depth evaluation of science and technology projects.However,the country's increasing investment in scientific research,the industry's demand for new technologies under the weight of corporate survival has not brought about the fruitful results of the transformation of scientific research results.The formation of such public opinion must be a blind spot in the middle link where policies,subsidies,and corporate culture are not yet involved..This research is based on the research and development of biomedical research with long development cycle,strict administrative supervision,low degree of monopoly,and weak business model.It is analyzed and found that the lack of stage technology trading mechanism and trading culture is biomedicine.The transformation of scientific research achievements in the field is not complete.Based on this,the paper further concludes that the innovation of biomedicine is a relay race,and the reason for the poor translation of scientific research results in China is that many policies and funding are focused on the first stick(the university's pioneering research)and the fourth stick(medicine).The convergence of the company's production.The difficulty of connecting the first stick and the fourth stick is also the source of many misunderstandings between enterprises and research universities in the combination of production,study and research..Based on the above analysis,this article refers to the different styles of Boston,Northern California,and Southern California,combined with the reform of China's biopharmaceutical new product regulations in recent years,and the maturity of the entrusted R&D industry,and then under the existing conditions of China,and made some suggestions for establishing a trading mechanism for phased technology.